Pluri Inc. (PLUR)
4.47
0.22 (5.30%)
At close: Jan 14, 2025, 3:45 PM
4.47
0.00%
After-hours Jan 14, 2025, 03:45 PM EST
undefined% (undefined)
| Bid | 4.22 |
| Market Cap | 24.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.11 |
| PE Ratio (ttm) | -1.09 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 4.53 |
| Volume | 11,945 |
| Avg. Volume (20D) | 24,795 |
| Open | 4.30 |
| Previous Close | 4.25 |
| Day's Range | 4.15 - 4.49 |
| 52-Week Range | 4.07 - 8.48 |
| Beta | undefined |
About PLUR
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respir...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2003
Employees 106
Stock Exchange NASDAQ
Ticker Symbol PLUR
Website https://pluri-biotech.com/
3 weeks ago ·
Source
+4.76%
Pluri shares are trading higher after the company ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+11.84%
Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.
